ArticleMateria socio-medica2025
Evaluation of Reproductive Hormones (FSH, LH, E2, and Prolactin) in Patients From Bosnia With Polycystic Ovary Syndrome.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic Ovary Syndrome (PCOS) is a widespread endocrine disorder affecting women of reproductive age, often associated with hormonal imbalances that disrupts the normal functioning of the ovaries. Key reproductive hormones involved include Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), Oestrogen (E2), and Prolactin. These disruptions can contribute to symptoms like irregular periods, infertility, weight gain, and emotional distress. Understanding the delicate balance of these hormones is essential for diagnosis and managing PCOS. Objective: The aim of this study was to evaluate and compare reproductive hormone levels including FSH, LH, E2, and prolactin in woman with PCOS and those with normal ovarian morphology. Methods: A total of 100 reproductive-age woman from Bosnia and Herzegovina were included, divided in control group (n=50) normal ovaries and PCOS group (n=50). Hormonal levels were measured and statistically analysed. Results: According to the obtained results, a statistically significant difference in LH levels and FSH/LH ratio between the PCOS and control group was observed. Women with PCOS exhibited elevated LH levels and a decreased FSH/LH ratio, indicating a hormonal shift in favour of LH. Although FSH levels in PCOS patients were lower, they remained within the lower reference range. No statistically significant differences were observed in E2 and Prolactin levels between the two groups. Conclusion: PCOS is characterized by altered reproductive hormone profiles, particularly elevated LH and a disrupted FSH/LH ratio, while E2 and Prolactin remain largely unaffected. These findings contribute to a better understanding of PCOS pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.